Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report)'s share price reached a new 52-week low on Tuesday . The company traded as low as $122.80 and last traded at $126.06, with a volume of 298645 shares changing hands. The stock had previously closed at $125.29.
Analyst Ratings Changes
A number of research analysts have recently issued reports on KRYS shares. Chardan Capital reiterated a "buy" rating and set a $219.00 price objective on shares of Krystal Biotech in a report on Wednesday, May 7th. Cantor Fitzgerald reissued an "overweight" rating and set a $215.00 price objective on shares of Krystal Biotech in a report on Thursday, February 20th. Jefferies Financial Group started coverage on Krystal Biotech in a research note on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price objective for the company. Guggenheim decreased their price target on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Finally, Citigroup lowered their price target on Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating for the company in a research report on Friday, May 16th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $211.13.
Read Our Latest Stock Analysis on Krystal Biotech
Krystal Biotech Stock Up 1.2%
The company has a 50-day simple moving average of $154.86 and a two-hundred day simple moving average of $164.80. The firm has a market cap of $3.67 billion, a PE ratio of 42.49 and a beta of 0.79.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). The business had revenue of $88.18 million for the quarter, compared to the consensus estimate of $98.66 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. As a group, equities analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.
Insiders Place Their Bets
In related news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the transaction, the insider now owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. This represents a 1.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 13.70% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the company. Strs Ohio purchased a new stake in Krystal Biotech in the 1st quarter worth about $1,244,000. Intech Investment Management LLC increased its stake in shares of Krystal Biotech by 11.4% in the first quarter. Intech Investment Management LLC now owns 12,078 shares of the company's stock worth $2,178,000 after purchasing an additional 1,239 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Krystal Biotech by 173.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company's stock valued at $103,764,000 after purchasing an additional 365,304 shares during the period. Woodline Partners LP lifted its stake in shares of Krystal Biotech by 0.4% during the 1st quarter. Woodline Partners LP now owns 222,043 shares of the company's stock valued at $40,034,000 after buying an additional 941 shares in the last quarter. Finally, S Squared Technology LLC boosted its holdings in Krystal Biotech by 2.1% in the 1st quarter. S Squared Technology LLC now owns 97,215 shares of the company's stock worth $17,528,000 after buying an additional 2,000 shares during the period. Hedge funds and other institutional investors own 86.29% of the company's stock.
About Krystal Biotech
(
Get Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Read More
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
